Recent Advances in Stem Cell Therapy for Parkinson’s Disease

The pathologic hallmark behind Parkinson’s disease (PD) is the loss of dopaminergic neurons from the substantia nigra pars compacta (SNpc) and accumulation of lewy bodies (mis-folded proteins). Clinically, in PD the patient encounter with both motor and non-motor symptoms, motor symptoms caused by loss of dopaminergic neurons from the substantia nigra, presented with tremor, bradykinesia and muscle rigidity along with impaired gait, and posture. Recent researches have enlightened the role of different type of stem cell and their clinical application. Stem cell therapy has shown promising effects on the lifestyle and behavioral changes in patients with Parkinson’s disease. In this review article we will be discussing about the recent advancements in stem cell therapy for Parkinson’s disease.

• Publication year

  2020

• Venue

  American Journal of Biomedical Science & Research

• Publication date

  2020-02-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.34297/ajbsr.2020.07.001158
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetics of Parkinson's disease

  2018cited by this paper
• Biology of GDNF and its receptors - Relevance for disorders of the central nervous system.

  2017cited by this paper
• Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease

  2016cited by this paper
• Understanding Dopaminergic Cell Death Pathways in Parkinson Disease.

  2016cited by this paper
• Effects of cellular origin on differentiation of human induced pluripotent stem cell-derived endothelial cells.

  2016cited by this paper
• Distribution and Load of Amyloid-&bgr; Pathology in Parkinson Disease and Dementia with Lewy Bodies

  2016cited by this paper
• Clinical translation of stem cell transplantation in Parkinson's disease

  2016cited by this paper
• Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis

  2016cited by this paper
• Stem cell transplantation therapy in Parkinson’s disease

  2015cited by this paper
• Applications of Induced Pluripotent Stem Cells in Studying the Neurodegenerative Diseases

  2015cited by this paper
• Structural basis of antizyme-mediated regulation of polyamine homeostasis

  2015cited by this paper
• CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases

  2015cited by this paper
• Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease.

  2015cited by this paper
• Neuropathologically mixed Alzheimer’s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes

  2015cited by this paper
• Is Parkinson's Disease Truly a Prion-Like Disorder? An Appraisal of Current Evidence

  2015cited by this paper
• Development of stem cell-based therapy for Parkinson’s disease

  2015cited by this paper
• Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease.

  2015cited by this paper
• Stem cell-based approach for the treatment of Parkinson's disease

  2015cited by this paper
• Forward engineering neuronal diversity using direct reprogramming

  2015cited by this paper
• The Development of Treatment for Parkinson's Disease

  2015cited by this paper
• CRISPR-Cas systems for editing, regulating and targeting genomes

  2014cited by this paper
• Generation of naive induced pluripotent stem cells from rhesus monkey fibroblasts.

  2014cited by this paper
• Which Patients with Parkinson's Disease Participate in Clinical Trials? One Centre's Experiences with a New Cell Based Therapy Trial (TRANSEURO)

  2014cited by this paper
• Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports.

  2014cited by this paper
• Human-induced pluripotent stem cells: potential for neurodegenerative diseases.

  2014cited by this paper
• Alpha-synuclein biology in Lewy body diseases

  2014cited by this paper
• Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson’s disease

  2014cited by this paper
• Human fetal striatum-derived neural stem (NS) cells differentiate to mature neurons in vitro and in vivo.

  2014cited by this paper
• Direct lineage reprogramming of mouse fibroblasts to functional midbrain dopaminergic neuronal progenitors.

  2014cited by this paper
• Protein Misfolding and Neurodegenerative Diseases

  2014influential reference
• A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells

  2014cited by this paper
• Understanding cognitive deficits in Parkinson's disease: lessons from preclinical animal models.

  2013cited by this paper
• Improved Cell Therapy Protocols for Parkinson's Disease Based on Differentiation Efficiency and Safety of hESC‐, hiPSC‐, and Non‐Human Primate iPSC‐Derived Dopaminergic Neurons

  2013cited by this paper
• Pluripotent stem cells for Parkinson's disease: progress and challenges

  2013cited by this paper
• Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-Molecule Compounds

  2013cited by this paper
• Corticostriatal connectivity and its role in disease

  2013cited by this paper
• Neuroprotective Function of DJ-1 in Parkinson's Disease

  2013cited by this paper
• Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.

  2013cited by this paper
• Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease

  2013cited by this paper
• Role of Oxidative Stress in Parkinson's Disease

  2013cited by this paper
• Efficient Generation of A9 Midbrain Dopaminergic Neurons by Lentiviral Delivery of LMX1A in Human Embryonic Stem Cells and Induced Pluripotent Stem Cells

  2012cited by this paper
• Parkinson's disease: gene therapies.

  2012cited by this paper
• Neural stem cells transplanted in a mouse model of Parkinson's disease differentiate to neuronal phenotypes and reduce rotational deficit.

  2012cited by this paper
• Process engineering of human pluripotent stem cells for clinical application.

  2012cited by this paper
• Suspended in culture--human pluripotent cells for scalable technologies.

  2012cited by this paper
• Scalable GMP compliant suspension culture system for human ES cells.

  2012cited by this paper
• Current status of clinical trials of neural transplantation in Parkinson's disease.

  2012cited by this paper
• Alpha-synuclein: from secretion to dysfunction and death

  2012cited by this paper
• Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy.

  2012cited by this paper
• In brief

  2011cited by this paper
• Direct generation of functional dopaminergic neurons from mouse and human fibroblasts

  2011cited by this paper
• Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons.

  2011cited by this paper
• Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells

  2011cited by this paper
• Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture.

  2011cited by this paper
• Epidemiology and etiology of Parkinson’s disease: a review of the evidence

  2011cited by this paper
• Recent advances in the genetics of Parkinson's disease.

  2011cited by this paper
• Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells

  2011cited by this paper
• Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio

  2011cited by this paper
• Functional integration of dopaminergic neurons directly converted from mouse fibroblasts.

  2011cited by this paper
• Mechanisms of nuclear reprogramming by eggs and oocytes: a deterministic process?

  2011cited by this paper
• The role of environmental exposures in neurodegeneration and neurodegenerative diseases.

  2011cited by this paper
• Transplantation of Neuronal-Primed Human Bone Marrow Mesenchymal Stem Cells in Hemiparkinsonian Rodents

  2011cited by this paper
• Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells

  2011cited by this paper
• Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules

  2011cited by this paper
• What genetics tells us about the causes and mechanisms of Parkinson's disease.

  2011cited by this paper
• Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD

  2011cited by this paper
• Identification and classification of chromosomal aberrations in human induced pluripotent stem cells.

  2010cited by this paper
• Progress toward the clinical application of patient-specific pluripotent stem cells.

  2010cited by this paper
• Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and 18F-FDOPA PET Outcomes

  2010cited by this paper
• Restorative approaches in Parkinson's Disease: which cell type wins the race?

  2010cited by this paper
• Transplantation of Undifferentiated Human Mesenchymal Stem Cells Protects against 6-Hydroxydopamine Neurotoxicity in the Rat

  2010cited by this paper
• Efficient derivation of functional floor plate tissue from human embryonic stem cells.

  2010cited by this paper
• Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats

  2010cited by this paper
• Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants

  2010cited by this paper
• Epigenetic memory in induced pluripotent stem cells

  2010cited by this paper
• A Novel Combination of Factors, Termed SPIE, which Promotes Dopaminergic Neuron Differentiation from Human Embryonic Stem Cells

  2009influential reference
• Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling

  2009cited by this paper
• Faculty Opinions recommendation of Human induced pluripotent stem cells free of vector and transgene sequences.

  2009cited by this paper
• 17-P022 Virus-free induction of pluripotency and subsequentexcision of reprogramming factors

  2009cited by this paper
• Regionally Specified Human Neural Progenitor Cells Derived from the Mesencephalon and Forebrain Undergo Increased Neurogenesis Following Overexpression of ASCL1

  2009cited by this paper
• Reprogramming of Human Somatic Cells Using Human and Animal Oocytes

  2009cited by this paper
• Supplemental Data Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins

  2009cited by this paper
• Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment.

  2009cited by this paper
• Induced pluripotent stem cells generated without viral integration

  2009cited by this paper
• Upping the ante: recent advances in direct reprogramming.

  2009cited by this paper
• Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors.

  2009cited by this paper
• Xeno-Free Defined Conditions for Culture of Human Embryonic Stem Cells, Neural Stem Cells and Dopaminergic Neurons Derived from Them

  2009cited by this paper
• Enhanced survival and function of neural stem cells‐derived dopaminergic neurons under influence of olfactory ensheathing cells in parkinsonian rats

  2009cited by this paper
• Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells.

  2009cited by this paper
• Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases

  2009cited by this paper
• Medical management of Parkinson's disease.

  2008cited by this paper
• Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain*

  2008cited by this paper
• Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts

  2008cited by this paper
• Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years

  2008cited by this paper
• Reprogramming of human somatic cells to pluripotency with defined factors

  2008cited by this paper
• Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease.

  2008cited by this paper
• Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease

  2008cited by this paper
• Human embryonic stem cells for brain repair?

  2008cited by this paper
• Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2

  2008cited by this paper
• Complex I deficiency in Parkinson's disease frontal cortex.

  2008cited by this paper

• No citing papers are available for this paper.